{'52WeekChange': 0.03941059,
 'SandP52WeekChange': 0.0644362,
 'address1': '6000 Shoreline Court',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 30.38,
 'askSize': 800,
 'averageDailyVolume10Day': 460375,
 'averageVolume': 477980,
 'averageVolume10days': 460375,
 'beta': 0.845378,
 'beta3Year': None,
 'bid': 30.41,
 'bidSize': 800,
 'bookValue': 4.608,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 30.81,
 'dayLow': 29.87,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -68.138,
 'enterpriseToRevenue': 11.56,
 'enterpriseValue': 1409852416,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650 243 6301',
 'fiftyDayAverage': 27.522285,
 'fiftyTwoWeekHigh': 32.48,
 'fiftyTwoWeekLow': 13.9,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 49685044,
 'forwardEps': -0.46,
 'forwardPE': -65.934784,
 'fromCurrency': None,
 'fullTimeEmployees': 354,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.01722,
 'heldPercentInstitutions': 1.02579,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/veracyte.com',
 'longBusinessSummary': 'Veracyte, Inc. operates as a genomic diagnostics '
                        'company in the United States and internationally. The '
                        'company offers Afirma Genomic Sequencing Classifier '
                        'and Xpression Atlas, which are used to identify '
                        'patients with benign thyroid nodules among those with '
                        'indeterminate cytopathology results in order to rule '
                        'out unnecessary thyroid surgery; Percepta Genomic '
                        'Sequencing Classifier for lung cancer; Envisia '
                        'Genomic Classifier that help physicians to '
                        'differentiate idiopathic pulmonary fibrosis from '
                        'other interstitial lung diseases without the need for '
                        'surgery; and Prosigna Breast Cancer Prognostic Gene '
                        'Signature Assay test for assessing risk of distant '
                        'recurrence. It sells its products through product '
                        'specialists, account managers, and medical science '
                        'specialists. Veracyte, Inc. has a strategic '
                        'collaboration with Johnson & Johnson Innovation and '
                        'the Lung Cancer Initiative at Johnson & Johnson to '
                        'advance the development and commercialization of '
                        'novel diagnostic tests to detect lung cancer at its '
                        'earliest stages; a research collaboration with Loxo '
                        'Oncology for the development of therapies for '
                        'patients with genetically defined cancers; and a '
                        'collaboration with Johnson & Johnson Services, Inc. '
                        'The company was formerly known as Calderome, Inc. and '
                        'changed its name to Veracyte, Inc. in March 2008. '
                        'Veracyte, Inc. was incorporated in 2006 and is '
                        'headquartered in South San Francisco, California.',
 'longName': 'Veracyte, Inc.',
 'market': 'us_market',
 'marketCap': 1518119680,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_42154124',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -22398000,
 'nextFiscalYearEnd': 1640908800,
 'open': 30.81,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 243 6300',
 'previousClose': 30.96,
 'priceHint': 2,
 'priceToBook': 6.5820317,
 'priceToSalesTrailing12Months': 12.447583,
 'profitMargins': -0.18365,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 30.81,
 'regularMarketDayLow': 29.87,
 'regularMarketOpen': 30.81,
 'regularMarketPreviousClose': 30.96,
 'regularMarketPrice': 30.81,
 'regularMarketVolume': 406923,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 50053400,
 'sharesPercentSharesOut': 0.1074,
 'sharesShort': 5376881,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5413097,
 'shortName': 'Veracyte, Inc.',
 'shortPercentOfFloat': 0.1086,
 'shortRatio': 11.49,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'VCYT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.464,
 'twoHundredDayAverage': 25.578705,
 'volume': 406923,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.veracyte.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}